Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study

INTRODUCTION: Colon cancer impacts the lives of Kansans and those across the United States. Epidermal growth factor receptor (EGFR) inhibitors, such as panitumumab and cetuximab, have gained popularity as first-line treatment for stage 4 colon cancer despite their toxicities and have been used by cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Braden M., Pham, Tony A., Young, Kate J., Bantis, Leonidas E., Sun, Weijing, Kasi, Anup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University of Kansas Medical Center 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409940/
https://www.ncbi.nlm.nih.gov/pubmed/36042840
http://dx.doi.org/10.17161/kjm.vol15.15975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409940/
https://www.ncbi.nlm.nih.gov/pubmed/36042840
http://dx.doi.org/10.17161/kjm.vol15.15975

Ejemplares similares